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Forty patients with severe bacterial infections due to micro-organisms known or
presumed to be sensitive to both study antibiotics, were randomized to receive
either imipenem with cilastatin, 500 mg/500 mg iv tid (20 patients), or cefotaxime,
2 g iv tid (20 patients). The types of infections observed were equally distributed
between the 2 groups, and consisted of 18 complicated urinary tract infections, 9
pneumonia, 7 bone and soft tissue infections, 4 septicaemia of unknown origin and
2 intravenous-catheter-related septicaemia. In the imipenem group, 12 patients were
bacteraemic, compared to 10 in the cefotaxime group. The micro-organisms
observed were evenly distributed with Escherichia coli (22 cases) and Klebsiella
pneumoniae (6 cases) being the most frequent Sixteen patients were cured in the
imipenem group and 15 in the cefotaxime group, while 2 and 2 improved, 2 and 1
relapsed and 0 and 2 did not respond to the therapy, respectively. In the imipenem
group, no clinical side effects were observed while 5 patients had mild reactions in
the cefotaxime group (2 fever, 1 skin rash, 1 oral candidiasis and 1 diarrhoea).
Imipenem thus appeared as effective and well tolerated as cefotaxime in the
treatment of severely infected patients.
Introduction
The introduction of a new antibiotic such as imipenem is almost always accompanied
by a detailed body of research information on its pharmacology (Follath et al., 1981;
Kropp et al., 1982), in-vitro activity (Kesado, Hashizume & Asahi, 1980; Livennore,
Williams & Williams, 1981; Livingston, Elliott & Cobbs, 1981; Cohn, Reiner & Reller,
1982; Kesado et al., 1982; Witte, Sapico & Canawati, 1982), performance in animal
studies (Kropp et al., 1980; Patamasucon & McCracken, 1982; Pennington & Johnson,
1982; Baumgartner & Glauser, 1983) and efficacy and tolerance in early clinical trials
(Calandra, Ricci & Brown, 1983; Tally, Ho & Gorbach, 1983) with relatively straight-
forward, if somewhat therapeutically unchaUenging, clinical material. We were,
therefore, all the more interested in the outcome of a study we recently completed, in
which we had the opportunity to gain experience with imipenem in a group of severely
ill patients, at a relatively early stage of the compound's research programme. The
results of this study, in which the new agent, administered together with its inhibitor of
renal tubular metabolism cilastatin, was compared with the established cephalosporin
cefotaxime, are presented in this paper.
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Study design and patient population
Our protocol permitted the treatment of a wide range of proven or suspected bacterial
infections in hospitalized patients of both sexes, between the ages of 18 and 75 years.
Having made certain that potential patients met all exclusion criteria, which included
terminal illness, known or presumed hypersensitivity, established or suspected
resistance of the infecting organism, severe cardiac, renal or hepatic illness, and
pregnancy and lactation, treatment was randomized to imipenem/cilastatin
500 mg/500 mg intravenously every 8 h, or cefotaxime 2 g intravenously every 8 h.
Therapy was maintained for a minimum of 5, and a maximum of 18 days.
All patients received a full physical examination at the start of the study, and were
reviewed daily during therapy. In the acute phase, vital signs were recorded at least
four-hourly, and at least daily during the convalescent period. Paired aerobic and
anaerobic blood cultures, together with cultures and Gram stains from all known or
suspected sites of infection, were obtained for each patient before therapy. Standard
antibiotic disc susceptibility tests, including the two test antibiotics, were part of the
routine pre-study investigations. Follow-up cultures from all sources were obtained
throughout the treatment period in accordance with the clinical course, but included
routine cultures from the primary site 48 h after the start of therapy and, for urinary
infections, at 1 week, and again at 6 weeks, following cessation of treatment.
In the assessment of treatment efficacy, the following definitions were used:
Cure Disappearance of clinical evidence of infection. Sterile cultures
obtained during, and 1 to 3 days after, therapy (and at the late
follow-up for urinary tract infections).
Improvement Marked reduction in clinical symptoms and bacteriological growth,
without complete disappearance within 14 days.
Relapse Cure during treatment; reappearance (with or without symptoms)
of the causative organism after conclusion of therapy.
Failure Absence of response to therapy.
Results
A total of 40 patients was studied, 20 in each treatment group. Table I details some of
the characteristics of this randomized population, which appears to be well balanced
for the parameters recorded. In all cases the degree of the infection was judged to be
severe. In addition, as shown in Table II the group presented challenging diagnostic
and management decisions, as the majority of patients had significant underlying
pathology.
The types of infections observed during the study period were evenly distributed
between the two treatment groups; with pyelonephritis, pneumonia, and bone and soft
tissue infections accounting for 85% of the total diagnoses. Tables III and IV present
an analysis of these data by organisms cultured, their presence in blood and
therapeutic outcome, for imipenem and cefotaxime, respectively. In the imipenem
group, 60% of the patients had positive blood cultures, compared with 50% of those
in the cefotaxime group. The overall cure rate for imipenem was 80%, and for
cefotaxime 75%. Two patients in the cefotaxime group, however, were regarded as
therapeutic failures, whereas no patients were so classified in the imipenem group. The
cefotaxime-treated infections showed only improvement in two cases, and one patient
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Table I. Patient characteristics
Patient number
Mean age (years ± S.D.)
male
^ f e m a l e
Mean duration of test therapy (days ± S.D.)
Number experiencing pre-study failure of
therapy with
—amoxycillin
—penicillin+chloramphenicol
—penicillin
—co-trimoxazole
—doxycycline
Imipenem
20
51-4±160
9
11
ll-8±3-5
3
3
1
1
—
Ccfotaxime
20
54-8±17-2
12
8
ll-5±2-9
2
—
1
2
1
had a relapse. The imipenem group had two improvements and two relapses. There
thus appeared to be no major differences in therapeutic efficacy between the two
antibiotics.
Particular attention was directed to recording the development of new resistant
organisms during therapy. Table V gives the results for imipenem and cefotaxime. These
data refer only to cases of asymptomatic microbiological colonization. Urinary
enterococci and Candida sp. were the most frequently identified resistant organisms in
both treatment groups. Pseudomonas aeruginosa resistant to imipenem was found in
the sputum of two patients receiving this antibiotic. In one case, there was evidence
that the Pseudomonas was sensitive to this antibiotic before the study start. One
patient showed symptomatic clinical infection as a result of the emergence of a
resistant pathogen during therapy. This was a 72-year-old man with prostatic adenoma
Table II. Frequency of significant underlying disorders
Number of occurrences
in treatment groups*
Condition Imipenem Cefotaxime
Cardiovascular disease (cardiac and arterial
insufficiency, hypertension) 3 4
Neurological disease (multiple sclerosis,
epilepsy, hemiplegia)
Cirrhosis (viral, alcoholic)
Connective tissue disorder
Diabetes mellitus
Chronic obstructive lung disease
Severe trauma
Surgery within 14 days preceding study
Cancer local
with metastases
chronic haematological
* Some patients had more than one underlying condition. Five patients in the cefotaxime group, and four
in the imipenem, had no underlying disorders.
4
1
0
3
0
3
4
1
1
1
1
3
3
3
2
0
1
1
0
1
Table ID. Nature of infections treated and therapeutic outcome—imipenem
Type of
infection Organism
No. of patients
No. of No. of positive
organisms blood cultures Cured Improved Relapsed Failure
Complicated
urinary tract
infection
(9 patients)*
Pneumonia
(4 patients)
Bone and soft
tissue
(4 patients)
Septicaemia of
unknown origin
(2 patients)
iv catheter
(1 patient)
E. coli
E. coli + Serratia
K. pneumoniae +
E. coli + Proteus
vulgaris
K. pneumoniae
Unknown
E. coli
Strep, pyogenes
Strep, pneumoniae
Group G streptococcus
Meningococcus group B
K. pneumoniae
K. pneumoniae
' Includes five cases for whom oral antibiotic therapy was continued for 4 weeks after the study period.
Table IV. Nature of infections treated and therapeutic outcome—cefotaxime
Type of
infection
Complicated
urinary tract
infection
(9 patients)*
Pneumonia
(5 patients)
Bone and soft
tissue
(3 patients)
Septicaemia of
unknown origin
(2 patients)
iv catheter
(1 patient)
Organism
E. coli
K. pneumoniae
E. coli
Mixed anaerobic flora
Unknown
E, coli +
Acinetobacter
Staph. aureus +
Strep, pyogenes
Staph. aureus
E. coli
K. pneumoniae
No. of patients
No. of No. of positive
organisms blood cultures Cured Improved Relapsed Failure
• Includes three cases for whom oral antibiotic therapy was continued for 4 weeks after the study period.
2
3
1
2*
2
4
1
1
1
1
146 J. D. Bamngartner and M. P. Glanser
Table V. Development of resistant strains (colonization)
No. of resistant organisms
in patients receiving
Source Organism imipenem cefotaxime
Enterococcus
. . . Candida spp.
U n n c
 Staph. epidermidis
Acinetobacter sp.
Wound Enterococcus
_ . Candida spp.
S P u t u m Ps. aerugZosa
* Present pre-study.
and bladder diverticulum who received cefotaxime for an Escherichia coli
pyelonephritis following bladder catheterization. The organism and the patient's
symptoms initially disappeared; but a symptomatic cefotaxime-resistant enterococcal
cystitis supervened. This was treated successfully with a course of nitrofurantoin.
Tolerance of the test drugs was assessed by the frequency of clinical side effects, and
deviations from the normal ranges of a battery of haematological and biochemical
tests performed before, during and after the study. None of the 20 patients who
received imipenem had a drug-related clinical adverse reaction. Five of the 20
cefotaxime-treated patients had side effects including diarrhoea (one case), fever (two
cases), skin rash (one case) and oral candidiasis (one case).
Laboratory screening produced the following results. In the cefotaxime group, two
patients developed mild elevations of alkaline phosphatase, and one patient a positive
Coombs' test, with no evidence of anaemia. In the imipenem group, there were four
mild alkaline phosphatase elevations and three weakly-positive asymptomatic
Coombs' tests. Five patients in the imipenem group were noted to have
thrombocytosis. Three cases were only moderate elevations, whereas two reached
maximum values of 1050 x 109/l and 1098 x 109/l, respectively (upper limit of normal,
350 x 109/l). These two cases received anti-aggregation therapy. The thrombocytoses
were regarded as possibly (four cases) or probably (one case) drug-related. In no case
was it considered necessary to alter or discontinue antibiotic therapy.
Although numerous medications were administered together with the test antibiotics
during the study, no suggestion of significant interactions was obtained from the
clinical or laboratory findings.
Discussion
All comparative antibiotic studies of this nature suffer to some extent from the
protocol exclusion of infections caused by organisms known or presumed to be
resistant to either drug. Thus, we were unable to include mixed flora intra-abdominal
infections; an indication for which the new antibiotic imipenem could be expected to
show interesting results. Within the limitations of the study design, however, we have
been able to demonstrate that the new compound compares well for therapeutic
efficacy with that of an established cephalosporin. It proved able to cure severe
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infections, such as complicated urinary-tract infections, pneumonia, bone and soft
tissue infections and septicaemia. More than half of these cases were bacteraemic.
There were no therapeutic failures in the imipenem group, and two cases were
judged as only improved (Table III), a patient with a paravesical abscess and a patient
with a pneumonia of unknown origin. There were two cases of relapse: a patient with
an E. coli vertebral osteomyelitis with bacteraemia, and a man with complicated
pyelonephritis.
In the cefotaxime group, 2 therapeutic failures were recorded (Table IV). Therapy
was stopped after 3 days in a 48-year-old chronic alcoholic patient with pulmonary
abscess, who developed a severe cellulitis of the foot, from which a cefotaxime-
resistant mixed anaerobic population was cultured. A second patient with severe
chronic lymphatic leukaemia and E. coli bacteraemia died on the eleventh day of
therapy after a transient improvement. There was one case of asymptomatic relapse
with cefotaxime, in a patient with acute complicated pyelonephritis.
Recently, there has been concern regarding the question of bacterial, especially
enterococcal, and fungal superinfection during therapy with the newer cephalosporins
(Yu, 1981). In our study, resistant strains of enterococci emerged in two patients in the
imipenem group, and in three in the cefotaxime group. One patient developed
symptomatic enterococcal lower urinary tract superinfection in this latter group.
Colonization with Candida albicans occurred in four patients receiving imipenem, and
in five receiving cefotaxime. Two patients were colonized with imipenem-resistant
Pseudomonas aeruginosa at the end of imipenem treatment.
Imipenem was not associated with drug-related clinical side effects in any of the
patients studied. The five cases of thrombocytosis in the imipenem group remain
difficult to assess. Thrombocytosis is certainly often a feature following severe
infections. Previous studies have apparently not uncovered any increased incidence of
this condition, and it would be difficult to postulate a possible mechanism. Cases of
local irritation at the infusion site occurred with similar frequency in both treatment
groups, and none were regarded as drug-related side effects.
In conclusion, we have shown that, in a group of severely infected patients, many of
whom had significant concomitant pathology, the new carbapenem antibiotic
imipenem was as effective therapeutically as the established cephalosporin cefotaxime.
No drug-related clinical side-effects occurred in any of the patients treated with the
new agent. It should, therefore, find a useful place in the therapy of a wide range of
infections in hospitalized patients.
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